• Je něco špatně v tomto záznamu ?

Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms

M. Kaisrlikova, D. Kundrat, P. Koralkova, I. Trsova, Z. Lenertova, H. Votavova, MD. Merkerova, Z. Krejcik, J. Vesela, M. Vostry, R. Simeckova, MS. Markova, M. Lauermannova, A. Jonasova, J. Cermak, V. Divoky, M. Belickova

. 2024 ; 154 (9) : 1652-1668. [pub] 20240105

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006502

Grantová podpora
UHKT,00023736 Ministry of Health of the Czech Republic
NU-21-03-00565 Ministry of Health of the Czech Republic
LX22NPO5102 Next Generation EU, Programme EXCELES
LM2023033 European Biobanking and Biomolecular Research Infrastructure
UNCE/MED/016 Charles University
JG_2023_016 UP Young Researcher Grant Competition

Patients with myelodysplastic neoplasms (MDS) are classified according to the risk of acute myeloid leukemia transformation. Some lower-risk MDS patients (LR-MDS) progress rapidly despite expected good prognosis. Using diagnostic samples, we aimed to uncover the mechanisms of this accelerated progression at the transcriptome level. RNAseq was performed on CD34+ ribodepleted RNA samples from 53 LR-MDS patients without accelerated progression (stMDS) and 8 who progressed within 20 months (prMDS); 845 genes were differentially expressed (ІlogFCІ > 1, FDR < 0.01) between these groups. stMDS CD34+ cells exhibited transcriptional signatures of actively cycling, megakaryocyte/erythrocyte lineage-primed progenitors, with upregulation of cell cycle checkpoints and stress pathways, which presumably form a tumor-suppressing barrier. Conversely, cell cycle, DNA damage response (DDR) and energy metabolism-related pathways were downregulated in prMDS samples, whereas cell adhesion processes were upregulated. Also, prMDS samples showed high levels of aberrant splicing and global lncRNA expression that may contribute to the attenuation of DDR pathways. We observed overexpression of multiple oncogenes and diminished differentiation in prMDS; the expression of ZEB1 and NEK3, genes not previously associated with MDS prognosis, might serve as potential biomarkers for LR-MDS progression. Our 19-gene DDR signature showed a significant predictive power for LR-MDS progression. In validation samples (stMDS = 3, prMDS = 4), the key markers and signatures retained their significance. Collectively, accelerated progression of LR-MDS appears to be associated with transcriptome patterns of a quiescent-like cell state, reduced lineage differentiation and suppressed DDR, inherent to CD34+ cells. The attenuation of DDR-related gene-expression signature may refine risk assessment in LR-MDS patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006502
003      
CZ-PrNML
005      
20240903090820.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34834 $2 doi
035    __
$a (PubMed)38180088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kaisrlikova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000188407654
245    10
$a Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms / $c M. Kaisrlikova, D. Kundrat, P. Koralkova, I. Trsova, Z. Lenertova, H. Votavova, MD. Merkerova, Z. Krejcik, J. Vesela, M. Vostry, R. Simeckova, MS. Markova, M. Lauermannova, A. Jonasova, J. Cermak, V. Divoky, M. Belickova
520    9_
$a Patients with myelodysplastic neoplasms (MDS) are classified according to the risk of acute myeloid leukemia transformation. Some lower-risk MDS patients (LR-MDS) progress rapidly despite expected good prognosis. Using diagnostic samples, we aimed to uncover the mechanisms of this accelerated progression at the transcriptome level. RNAseq was performed on CD34+ ribodepleted RNA samples from 53 LR-MDS patients without accelerated progression (stMDS) and 8 who progressed within 20 months (prMDS); 845 genes were differentially expressed (ІlogFCІ > 1, FDR < 0.01) between these groups. stMDS CD34+ cells exhibited transcriptional signatures of actively cycling, megakaryocyte/erythrocyte lineage-primed progenitors, with upregulation of cell cycle checkpoints and stress pathways, which presumably form a tumor-suppressing barrier. Conversely, cell cycle, DNA damage response (DDR) and energy metabolism-related pathways were downregulated in prMDS samples, whereas cell adhesion processes were upregulated. Also, prMDS samples showed high levels of aberrant splicing and global lncRNA expression that may contribute to the attenuation of DDR pathways. We observed overexpression of multiple oncogenes and diminished differentiation in prMDS; the expression of ZEB1 and NEK3, genes not previously associated with MDS prognosis, might serve as potential biomarkers for LR-MDS progression. Our 19-gene DDR signature showed a significant predictive power for LR-MDS progression. In validation samples (stMDS = 3, prMDS = 4), the key markers and signatures retained their significance. Collectively, accelerated progression of LR-MDS appears to be associated with transcriptome patterns of a quiescent-like cell state, reduced lineage differentiation and suppressed DDR, inherent to CD34+ cells. The attenuation of DDR-related gene-expression signature may refine risk assessment in LR-MDS patients.
650    _2
$a lidé $7 D006801
650    _2
$a transkriptom $7 D059467
650    _2
$a buněčná adheze $7 D002448
650    12
$a myelodysplastické syndromy $x genetika $7 D009190
650    _2
$a buněčný cyklus $7 D002453
650    _2
$a oprava DNA $7 D004260
650    12
$a nádory $7 D009369
650    _2
$a kinasy NEK $x genetika $x metabolismus $7 D000072379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kundrat, David $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000347701229
700    1_
$a Koralkova, Pavla $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000179701501
700    1_
$a Trsova, Iva $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic $1 https://orcid.org/000000026594776X
700    1_
$a Lenertova, Zuzana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0009000357458856
700    1_
$a Votavova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/000000022990579X $7 xx0081900
700    1_
$a Merkerova, Michaela Dostalova $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000263459180 $7 xx0164071
700    1_
$a Krejcik, Zdenek $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000283212644
700    1_
$a Vesela, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000215856763
700    1_
$a Vostrý, Martin $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000275572543 $7 xx0321711
700    1_
$a Simeckova, Radka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Markova, Marketa Stastna $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000322065246 $7 xx0101281
700    1_
$a Lauermannova, Marie $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Jonasova, Anna $u First Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000302461524 $7 xx0103767
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Divoky, Vladimir $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/000000030202245X $7 xx0018902
700    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/000000029158881X $7 xx0099634
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 154, č. 9 (2024), s. 1652-1668
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38180088 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240903090817 $b ABA008
999    __
$a ok $b bmc $g 2080850 $s 1216269
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 154 $c 9 $d 1652-1668 $e 20240105 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a UHKT,00023736 $p Ministry of Health of the Czech Republic
GRA    __
$a NU-21-03-00565 $p Ministry of Health of the Czech Republic
GRA    __
$a LX22NPO5102 $p Next Generation EU, Programme EXCELES
GRA    __
$a LM2023033 $p European Biobanking and Biomolecular Research Infrastructure
GRA    __
$a UNCE/MED/016 $p Charles University
GRA    __
$a JG_2023_016 $p UP Young Researcher Grant Competition
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace